Lenalidomide Glenmark (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, changing the complex’s target profile. This triggers degradation of specific transcription factors, leading to reduced cytokine production, inhibition of new blood‑vessel formation, and enhanced activity of T‑cells and natural‑killer cells, which together produce anti‑tumor effects.

The dosage of Lenalidomide Glenmark is individualized by the treating physician based on the specific indication, patient characteristics, and laboratory parameters. Only a qualified prescriber can determine the appropriate strength, schedule, and duration of therapy.

Lenalidomide is classified as a high‑risk medication for fetal harm. Women of child‑bearing potential must use effective contraception, and the drug should not be used during pregnancy. Safety during breastfeeding has not been established, so breastfeeding is generally discouraged while on therapy.

To request Lenalidomide Glenmark, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and the necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class and is often used in combination with dexamethasone or proteasome inhibitors. Compared with traditional chemotherapy, it offers a different mechanism—modulating the immune system and inhibiting angiogenesis—while providing comparable efficacy in many patients and a distinct side‑effect profile.

Store Lenalidomide Glenmark at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Lenalidomide Glenmark is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and whether it should be taken on an empty stomach depend on the individual treatment plan.

Serious risks include severe neutropenia, severe thrombocytopenia, venous thromboembolism, secondary primary cancers, and severe allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, bleeding, or clot formation, and any concerning symptoms should be reported immediately.

Lenalidomide Glenmark should be avoided in patients with known hypersensitivity to lenalidomide or any of its excipients, in those who are pregnant or not using effective contraception, and in individuals with uncontrolled infections or severe organ dysfunction where the risk outweighs potential benefit.